Koers Kane Biotech Inc Toronto S.E.
Aandelen
KNE
CA4838092084
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 2,67 mln. 1,95 mln. 1,81 mln. | Omzet 2023 | 149K 109K 101K | Marktkapitalisatie | 10,55 mln. 7,71 mln. 7,16 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -3 mln. -2,19 mln. -2,04 mln. | Nettowinst (verlies) 2023 | -5 mln. -3,65 mln. -3,39 mln. | EV/omzet 2022 | 6,37 x |
Nettoschuld 2022 | 5,76 mln. 4,21 mln. 3,91 mln. | Nettoschuld 2023 | 8,51 mln. 6,22 mln. 5,78 mln. | EV/omzet 2023 | 128 x |
K/w-verhouding 2022 |
-2,79
x | K/w-verhouding 2023 |
-2,02
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 65,07% |
Recentste transcriptie over Kane Biotech Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Edwards
CEO | Chief Executive Officer | - | 02-06-16 |
Ray Dupuis
DFI | Director of Finance/CFO | - | 05-09-17 |
Compliance Officer | - | 12-08-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
R. Renaud
BRD | Director/Board Member | - | 15-09-10 |
Chairman | 59 | 20/02 | |
Georges Morin
BRD | Director/Board Member | - | 20-05-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |